Department of Otolaryngology and F.M. Kirby Neurobiology Center, Boston Children's Hospital, 300 Longwood Avenue, Boston, MA, 02115, USA.
Department of Otolaryngology, Harvard Medical School, Boston, MA, 02139, USA.
Nat Commun. 2019 Jan 22;10(1):236. doi: 10.1038/s41467-018-08264-w.
Fifty percent of inner ear disorders are caused by genetic mutations. To develop treatments for genetic inner ear disorders, we designed gene replacement therapies using synthetic adeno-associated viral vectors to deliver the coding sequence for Transmembrane Channel-Like (Tmc) 1 or 2 into sensory hair cells of mice with hearing and balance deficits due to mutations in Tmc1 and closely related Tmc2. Here we report restoration of function in inner and outer hair cells, enhanced hair cell survival, restoration of cochlear and vestibular function, restoration of neural responses in auditory cortex and recovery of behavioral responses to auditory and vestibular stimulation. Secondarily, we find that inner ear Tmc gene therapy restores breeding efficiency, litter survival and normal growth rates in mouse models of genetic inner ear dysfunction. Although challenges remain, the data suggest that Tmc gene therapy may be well suited for further development and perhaps translation to clinical application.
50%的内耳疾病是由基因突变引起的。为了开发针对遗传性内耳疾病的治疗方法,我们设计了基因替代疗法,使用合成的腺相关病毒载体将跨膜通道样(Tmc)1 或 2 的编码序列递送到因 Tmc1 和密切相关的 Tmc2 突变而导致听力和平衡缺陷的小鼠的感觉毛细胞中。在这里,我们报告了功能在内耳和外毛细胞中的恢复,毛细胞存活率的提高,耳蜗和前庭功能的恢复,听觉皮层中神经反应的恢复以及对听觉和前庭刺激的行为反应的恢复。其次,我们发现内耳 Tmc 基因治疗可恢复遗传性内耳功能障碍小鼠模型的繁殖效率,窝仔存活率和正常生长速度。尽管仍然存在挑战,但数据表明 Tmc 基因治疗可能非常适合进一步开发,也许可以转化为临床应用。